Latest Stories
Featured Stories
Explore inspiring journeys of recovery and resilience as patients share their experiences with Padaav’s root-cause-focused, evidence-based Ayurvedic treatments, highlighting the power of personalized care and holistic healing.
Feedback
All Stories
Delve into the heartfelt experiences of patients who have transformed their health and lives with Padaav’s research-backed Ayurvedic care, showcasing the impact of addressing root causes for lasting recovery.
Hamad Alam
Rectal Adenocarcinoma
New Delhi
Hamad’s struggle reached a terrifying peak in 2018 while traveling back to Delhi from a cou…
Shilipi
Acute Recurrent Pancreatitis
Kotdwar, Uttarakhand.
Shilpi’s struggle began suddenly during her 10th-grade school break, when she felt a sharp …
Anurag Goyal
Investment Banker
New Delhi
Anurag’s struggle began suddenly in the midnight of September 2010, when he experienced exc…
Sumit Kumar
Pancreas Divisum with secondary Chronic Pancreatitis
Dehradun, Uttarakhand
Sumit suffered from Pancreas Divisum, a congenital anomaly where the two pancreatic ducts (the ve…
Aviral Saxena
Chronic Pancreatitis with Secondary Diabetes
Dehradun, Uttarakhand
Aviral’s journey began in November 2022 while he was actively working as a freelancer. The …
Rajeev Sharma
Chronic Pancreatitis
Dehradun, Uttarakhand
Rajeev’s journey began with mild symptoms in 2009, potentially following a physical encount…
Research
Our Research
At Padaav, alongside delivering unparalleled patient care and promoting holistic health, we are committed to advancing Ayurveda by actively participating in research and contributing to its growing body of knowledge.
Clinical Intervention of Ayurvedic Treatment in the Patients of Recurrent Acute/Chronic Pancreatitis
The study of 1233 acute pancreatitis patients found that 12.9% experienced oral feeding intolerance (OFI). Risk factors included younger age, male sex, alcohol use, smoking, non-biliary etiology, and SIRS at 48h. SIRS at 48h (OR 2.85) and non-biliary etiology (OR 1.77) were independently linked to OFI, with biliary etiology being protective.
Treatment of relapsed undifferentiated acute myeloid leukemia (AML-M0) with Ayurvedic therapy
A 16-year-old boy with AML-M0 relapsed after chemotherapy in 1997. He opted for Ayurvedic therapy (AYT) instead of further treatment. After six months, he was in remission and continued AYT for five years, with intermittent maintenance for two years. He has been disease-free and healthy for 12 years.
Immunomodulatory Effects of a Herbo-Mineral Ayurvedic Formulation in Experimental Models
IMMBO, a herbo-mineral Ayurvedic formulation, shows promise as an immune-modulator in immunosuppressed rats. It enhances immunity, blocks histamine release, and modulates key molecules like TNF-α and NF-κB, offering potential for allergic and immune-related disorders.
Ayurvedic treatment protocol in the management of pancreatitis: A nonrandomized observational study
A North Indian clinic treated 1750 recurrent pancreatitis patients (1997–2023) with an ayurvedic Herbo-Mineral Formulation (HMF). Among 916 completing 1-year treatment, attacks reduced by 93%, hospitalizations by 97%, with no adverse effects. Long-term remission supports further clinical trials.
Observational research on the effect of an Ayurvedic treatment protocol in patients of hereditary pancreatitis
Hereditary pancreatitis (HP) is a chronic genetic disorder with limited treatment options. This study evaluated the efficacy of a year-long Ayurvedic Treatment Protocol (ATP) in 151 patients, 88 of whom completed the program. The treatment included Ayurvedic formulations, dietary adjustments, and discontinuation of pancreatic enzymes. Results showed a 92.8% reduction in attack frequency and a 98.7% decrease in hospitalizations (p < 0.0001), with no adverse effects. ATP demonstrated safety and effectiveness in managing HP, suggesting the need for further research.
Proof of Efficacy Study to Evaluate an Ayurvedic Formulation in the Treatment of Allergic Rhinitis: An Open Label Randomized Controlled Clinical Trial
A study on 250 patients compared the Ayurvedic formulation IMMBO to a levocetirizine-montelukast combination for allergic rhinitis. IMMBO showed significantly greater improvements in symptoms (TNSS: -5.70 vs. -3.31) and IgE reduction (-351.54 vs. -208.79), demonstrating superior efficacy and safety.